US20070077295A1 - Method and composition for pharmaceutical product - Google Patents
Method and composition for pharmaceutical product Download PDFInfo
- Publication number
- US20070077295A1 US20070077295A1 US11/452,472 US45247206A US2007077295A1 US 20070077295 A1 US20070077295 A1 US 20070077295A1 US 45247206 A US45247206 A US 45247206A US 2007077295 A1 US2007077295 A1 US 2007077295A1
- Authority
- US
- United States
- Prior art keywords
- composition
- tenofovir
- emtricitabine
- granules
- efavirenz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- BESRNQGSLODRNZ-PHNLGHSNSA-N CC(C)OC(=O)OCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=CN=C2NCNC1=NC=NC2=C1N=CN2C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)OCOC(=O)OC(C)C.CC(C)OC(=O)OCOP(=O)(O)CO[C@H](C)CN1C=NC2=C1N=CN=C2NCNC1=NC=NC2=C1N=CN2C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C Chemical compound CC(C)OC(=O)OCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=CN=C2NCNC1=NC=NC2=C1N=CN2C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)OCOC(=O)OC(C)C.CC(C)OC(=O)OCOP(=O)(O)CO[C@H](C)CN1C=NC2=C1N=CN=C2NCNC1=NC=NC2=C1N=CN2C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C BESRNQGSLODRNZ-PHNLGHSNSA-N 0.000 description 1
- XLYSRKLPLHUWCJ-SNVBAGLBSA-N CC(C)OC(=O)OCOP(=O)(O)CO[C@H](C)CN1C=NC2=C1N=CN=C2N Chemical compound CC(C)OC(=O)OCOP(=O)(O)CO[C@H](C)CN1C=NC2=C1N=CN=C2N XLYSRKLPLHUWCJ-SNVBAGLBSA-N 0.000 description 1
- KOGYOPLNKQJQFM-NTSWFWBYSA-N O=C1NC(=O)N([C@@H]2CS[C@H](CO)O2)C=C1F Chemical compound O=C1NC(=O)N([C@@H]2CS[C@H](CO)O2)C=C1F KOGYOPLNKQJQFM-NTSWFWBYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/002—Compounding apparatus specially for enteral or parenteral nutritive solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Definitions
- This application relates to products for the treatment of viral infections, in particular HIV infections, using the known antiviral compounds efavirenz (tradename Sustiva, also known as EFV), emtricitabine (tradename Emtriva, also known as FTC) and tenofovir DF (disoproxil fumarate, also known as TDF) (tradename Viread, sold in combination with emtricitabine under the tradename Truvada).
- EFV efavirenz
- Emtriva also known as FTC
- tenofovir DF disoproxil fumarate
- Truvada product is produced by wet granulation of emtricitabine and tenofovir DF (WO 04/64845), which under the circumstances produces a chemically stable dosage form. This product does not contain efavirenz.
- triple combination HIV therapy using efavirenz as well as emtricitabine and tenofovir DF has been considered desirable. (hereafter “triple combination”; see WO 04/64845). Manufacturing a commercially viable triple combination product, however, would require that the final product meet stringent FDA requirements for bioequivalence to the commercial products, Viread (tenofovir disoproxil fumarate), Emtriva (emtricitabine), and Sustiva (efavirenz), and that the tablet be of suitable size for patients to easily swallow.
- Viread tenofovir disoproxil fumarate
- Emtriva emtricitabine
- Sustiva efavirenz
- combination tablets were manufactured by wet granulating the efavirenz component with the surfactant and other excipients, separately manufacturing the Truvada component using dry granulation, mixing the granulates together, compressing the mixture into tablets, and then film-coating the tablets.
- this approach also failed to produce the desired bioequivalence in between the commercial product, Sustiva (efavirenz), and clinical trial material (i.e., proposed commercial triple combination product).
- a novel and inventive step was needed to overcome the shortcomings of more straight-forward approaches to a triple combination dosage form.
- the stability and bioequivalence objectives for the triple combination tablet ultimately were achieved in an exemplary embodiment by dry granulating the emtricitabine/tenofovir disoproxil fumarate component, wet granulating the efavirenz component and, rather than using the straight-forward process of simply combining the granulates, instead organizing the granulates to produce a multilaminate dosage form, one component containing the emtricitabine/tenofovir disoproxil fumarate element, the other containing the efavirenz element. This minimized the contact of the tenfovir DF with surfactant, yet maintained the efavirenz excipients and process features that contributed to achieving bioequivalence.
- Truvada preparations WO04/64845
- these preparations typically contain relatively low proportions of excipient to API, on the order of to 1:1.
- Wet granulation of a preparation in which the proportion of excipient had been reduced to manageable amounts for a triple combination tablet unexpectedly resulted in a chemically unstable preparation.
- the inventors believe that so much water is required in the wet granulation of efavirenz (which has relatively low solubility in comparison to emtricitabine and tenofovir DF) that the latter two APIs dissolve into a eutectic mixture.
- a stable preparation of emtricitabine/tenofovir DF is provided by dry granulating a composition comprising a pharmaceutically acceptable excipient, tenofovir DF and emtricitabine.
- the omission of destabilizing amounts of water from the granulation process eliminates the disadvantageous formation of an emtricitabine/tenofovir DF eutectic mixture and enhances the stability of the resulting pharmaceutical product.
- the practice of the method of this invention produces a composition comprising dry granulated emtricitabine and tenofovir DF.
- Dry granulation is a well-known pharmaceutical manufacturing process per se.
- API is combined with excipients and lubricant excipient and then compressed to form a mass.
- This mass typically is then comminuted or milled, then sieved to obtain the desired size of particle.
- the granular product is compressed into tablets, filled into capsules or otherwise formed into a unitary dosage form in conventional fashion.
- This invention at least in part is directed to the products produced by this process.
- Compression into a mass is accomplished by conventional equipment.
- the API and excipients are passed through a roller compactor or chilsonator apparatus for compaction.
- other means for compacting e.g., compaction into slugs (or “slugging”), the API/excipient mixture optionally are used. This in turn is comminuted or milled, and then optionally sieved to produce the desired size granules.
- a dry granulated composition comprising emtricitabine and tenofovir DF is defined as the product of a dry granulation process.
- This composition essentially retains the crystalline APIs and is substantially free of dried eutectic emtricitabine/tenofovir DF. It typically will contain less than about 15% by weight dried eutectic mixture, ordinarily less than about 10% and generally less than about 5%.
- Dry granulated compositions include the direct product of dry granulation, i.e., dry granules per se, as well as products made from such granules including tablets, capsules, suppositories and other pharmaceutical dosage forms. Forming the dry granules into such physical forms substantially retains the character of the dry granular starting material and does not result in a substantial change in the properties of the granular component of the physical form presented.
- Dry granulation is conducted in the absence of a destabilizing amount of water, “destabilizing” being that amount of liquid water that is capable causing degradation (defined infra) of tenofovir DF and/or emtricitabine. Ordinarily, no water at all is added during the dry granulation process.
- Bound, entrained or absorbed water are commonly present in excipients. This water will not significantly adversely affect the stability of tenofovir DF and thus is not excluded from the invention.
- liquid water (added or generated in situ) from any source, e.g., chemical reactions, condensation, entrained ice, or the like is to be excluded from the granulation.
- minor amounts of liquid water optionally are added during granulation. These typically would be less than about 5% by weight, ordinarily less than about 1% by weight, however the water is generated or supplied. Water is present in the final granulation product up to about 10% by weight (Karl Fischer), but preferably is less, as low as 0.1% by weight.
- permitted quantities of water may vary depending upon other factors in the granulation, e.g., excipient type, temperature and so forth. For example, if a hygroscopic excipient is included this will convert added water into a bound form. All that is necessary is that the water not result in degradation of tenofovir DF in the final product. In general, water is excluded both from the pregranulation stage (preparation of the composition to be used directly in the granulation) as well as during the granulation process itself.
- Dry granulation results in a product that contains minimal amounts of water.
- the amount of water in the product granulate or dosage forms made there from are measured by loss on drying (LOD) or by the Karl Fischer method.
- the LOD of compositions of this invention are about 15%, about 10%, about 5% or typically less than about 3% by weight.
- the Karl Fischer water is about from 0.1 to 10% by weight, usually less than about 5% by weight, or less than about 2%.
- the amount of water in the final preparations, as opposed to the granulates is a function of granulate water as well as minor amounts of water used during subsequent process steps such as coating. These amounts of water added in later steps than granulation generally will not affect the stability of the emtricitabine/tenofovir DF APIs, and therefore are subject to considerable permitted variation.
- “Degradation” of tenofovir DF is the generation—in pharmaceutically unacceptable amounts—of at least one of the degradation products mono-POC PMPA, dimer or mixed dimer. “Degradation” of FTC is defined as the generation—in pharmaceutically unacceptable amounts—of FTU. These degradation products are shown below. Mono-POC PMPA Dimeric Degradation Products
- a “pharmaceutically unacceptable amount” is defined as the following amounts of each degradation product.
- Degradation products optionally are assayed in either an absolute or incremental amount.
- the absolute or total amount of degradation product is simply the amount found in the test article.
- the incremental amount is the additional amount of degradation product appearing in the product over that which was present (if any) in the API starting material.
- the amount of degradation product(s) optionally are measured at either or both of two points in time. One is the time of release into the marketplace. The other is after exposure to storage conditions under the conditions described below, i.e., the shelf life as set forth below.
- the percentage of degradation products is the amount of degradation product as measured by HPLC retention time comparison.
- HPLC retention time comparison the retention time of the main peaks observed in the tablets is required to be within 2% of the retention time of the main peaks in the a reference standard preparation containing efavirenz, emtricitabine, and tenofovir DF in an assay which has been shown to be specific for efavirenz, emtricitabine, and tenofovir DF.
- the percentage is determined by dividing the total amount of tenofovir DF plus the three degradation products into the amount of individual degradation product as determined by the HPLC assay.
- a small amount of water might be desirably present during a dry granulation.
- This water might be added in the liquid form as an incidental solubilizing agent for an excipient included in the composition to be compressed. It also might be added bound to a hygroscopic excipient containing an unusually large amount of absorbed water. If the resulting product upon release did not contain more than the specified approximate limits of any one or more of the 4 contaminants listed under any of the 4 assay paradigms above, then the process concerned would still be considered a dry granulation process.
- the artisan may adopt more stringent standards (i.e., the amounts of some contaminants may be less than set forth above), but this will be a matter of choice and shall not limit the scope of this invention.
- This embodiment entails the preparation of a triple combination tablet containing efavirenz, emtricitabine, and tenofovir DF.
- the last two drugs/excipients are segregated in a portion of the tablet, which is separate from, but in contact with, the portion of the tablet containing efavirenz/excipients.
- the emtricitabine and tenofovir DF component of the tablet which is an embodiment of this invention, optionally is manufactured for example as a stand-alone product and not necessarily in assembly with an efavirenz component.
- the emtricitabine/tenofovir DF dry granulation intermediate described below is optionally combined with other APIs or excipients, and compressed into tablets or conventionally processed into other conventional unitary dosage forms such as capsules, cachets, suppositories, or the like.
- the manufacturing method for the triple combination tablet employs two separate granulation steps.
- the efavirenz final blend (efavirenz and excipients) was produced by a wet granulation process whereas emtricitabine, tenofovir DF, and suitable excipients were blended and dry granulated by a roller compaction process.
- the final blends were compressed into a bilayer tablet which in turn was film-coated with an immediate release coating.
- the quantitative compositions of the efavirenz powder blend, FTC/TDF powder blend, and film-coated bilayer EFV/FTC/TDF tablets are listed in Table 1, Table 2, and Table 3, respectively.
- the quantities of efavirenz, emtricitabine, and tenofovir DF were adjusted for drug content factors (DCF) if the value was less than 0.99 with a concomitant reduction to the quantity of microcrystalline cellulose in each granulation.
- Efavirenz was wet granulated using a Niro-Fielder PMA-400 equipment train. Efavirenz, microcrystalline cellulose and sodium lauryl sulfate (Table 1) were added to the PMA-400 and blended for 3 minutes. Croscarmellose sodium and hydroxypropyl cellulose (Table 1) were added to the pre-mix and blended for an additional 2 minutes. Purified water was added to form a suitable granulation followed by additional wet massing after water addition. Table 4 lists the summary of granulation parameters used for two representative lots and sub parts. All sub parts used a water to efavirenz ratio of 1.30 except for AB509 Mix C which used a 1.25 ratio of water to efavirenz.
- the wet granules were milled, then dried to an LOD less than or equal to 1.5%.
- the dried granules were milled and blended with magnesium stearate (Table 1).
- the bulk density, particle size, and moisture content by LOD of the efavirenz granulations are listed in the first three lines of Table 5 (the B lot numbers are efavirenz products, the C lot numbers are emtricitabine/tenofovir DF).
- Particle size was determined by sifting 10-gram samples through 3-inch diameter screens using a sonic sifter (Model L3P, ATM Corporation, Milwaukee, Wis., USA). The following US Standard Mesh sizes (openings) were used: #20 (850 ⁇ m), #30 (600 ⁇ m), #40 (425 ⁇ m), #60 (250 ⁇ m), #80 (180 ⁇ m), and #250 (63 ⁇ m).
- the agitation and pulse were set at 7 and the sifting time was 5 minutes.
- the amount of powder retained on the sieves and the fines collector was determined by calculating the difference in weight before and after sifting.
- the geometric mean particle size was calculated by logarithmic weighting of the sieved distribution.
- Bulk density was determined by filling a 100-mL graduated cylinder with sample and calculating the difference in weight between the empty and full graduated cylinder per unit volume. In typical embodiments the bulk density of the granules is about from 0.25 to 0.75 g/mL.
- Moisture content measurements by loss on drying (LOD) were performed by heating a 2.5 g sample at 85° C. for 15 minutes using a heat lamp/balance system (Model LP16/PM400, Mettler-Toledo, Columbus, Ohio, USA).
- the granulations had similar bulk densities (0.54 to 0.56 g/mL) and similar geometric mean particle size distributions (215 to 268 ⁇ m).
- the LOD values of the final blend were consistent from 0.98 to 1.80%.
- the individual sieve distributions for the efavirenz granulations are listed in Table 6.
- Emtricitabine, microcrystalline cellulose, tenofovir DF, and croscarmellose were blended in a 650 L tote bin using a Gallay blender for 10 minutes.
- Magnesium stearate (Table 2) was added and blended for an additional 5 minutes. This pre-blend was then transferred to a 320-L Matcon bin fitted with a cone valve discharging station to assist with material transfer into the roller compactor hopper.
- the pre-blend was roller compacted using a Gerteis Macro-Pactor model 250/25/3 with 250 mm diameter by 50 mm wide smooth rolls.
- the roll gap thickness (2 mm), roll speed (10 rpm), compaction force (4 kN/cm), oscillating mill speed (75 rpm clockwise and counterclockwise), and oscillating mill screen opening (1.25 mm) were kept constant for all batches.
- the oscillating mill angle of rotation was also the same for all lots at 150° clockwise and 140° counterclockwise.
- roller compaction process proceeded without any apparent sign of heat accumulation on the equipment, product build-up, or melting.
- the granulations then were blended with extragranular croscarmellose sodium (34% of total amount) and magnesium stearate (47% of total amount).
- the particle size, bulk density, and LOD of the emtricitabine/tenofovir DF dry granulations were all similar for the three batches and are listed in Table 5 (bottom 3 compartments).
- the geometric particle sizes were very similar at from 330 to 344 ⁇ m.
- Bulk densities ranged from 0.59 to 0.60 g/mL.
- the final blend LOD values were consistent from 0.91 to 1.02%.
- the final powder blends have remarkably consistent physical properties.
- the efavirenz and tenofovir DF granulations each have geometric mean particle sizes that optionally range about from 100 to 600 ⁇ m, bulk densities optionally ranging about from 0.1 to 1 g/mL and LOD values optionally ranging about from 0.1 to 5% by weight.
- Efavirenz granulation and extragranular magnesium stearate were adjusted appropriately based on the yield of emtricitabine/tenofovir DF dry granulation.
- Efavirenz granulation and emtricitabine/tenofovir DF dry granulation were blended in a 3 cubic foot V-blender for 10 minutes.
- Magnesium stearate was added and blended an additional 5 minutes. Samples of the final powder blend were taken from 10 different locations after blending and analyzed for blend uniformity.
- the efavirenz and emtricitabine/tenofovir DF final powder blends showed acceptable blend uniformity and homogeneity for all three active ingredients indicating the robustness of the formulation regardless of the particle size or bulk density of emtricitabine/tenofovir DF dry granulations and efavirenz granulations.
- the granulations and blending procedure would be satisfactory for the formulation on a larger scale.
- Efavirenz/emtricitabine/tenofovir DF final powder blend was compressed into tablet cores using a Stokes Genesis Model 757, 41 station bilayer tablet press equipped plain-faced upper/ embossed “123” lower, capsule-shaped (20.0 mm ⁇ 10.4 mm) punches.
- the target mass of the tablet cores was 1550 mg.
- Samples of the core tablets were taken from a minimum of 20 equally spaced locations during the compression run and analyzed for content uniformity. In general, all powder blends compressed satisfactory on the rotary tablet press with respect to tablet hardness, friability, tablet thickness, tablet appearance, and tablet weight variation.
- the compression operation was performed at a rate of approximately 500 tablets/minute (12 rpm press speed) or approximately 0.8 kg/minute to deliver satisfactory tablet weight uniformity.
- Suitable film coatings are selected by routine screening of commercially available preparations. This activity is well within the skill of the ordinary artisan. Each lot of tablet cores was divided into two coating sub-lots that were film coated in a 48-inch Thomas Engineering COMPU-LAB coating pan using a dual-nozzle spraying system. All the tablet cores were film-coated using a 15% w/w aqueous coating suspension Opadry II pink, which was used within 24 hours of preparation. All tablet cores were coated to a target weight gain of 3.0% using a target spray rate of 180 g/min, which corresponds to a normalized spray rate of 1.5 to 2.3 g/min/kg tablets.
- Efavirenz/emtricitabine/tenofovir DF tablets are assayed by HPLC for EFV, FTC, and TDF using external reference standards.
- the degradation products of EFV, FTC, and TDF are determined by area normalization with the application of relative response factors, as appropriate.
- the identity of EFV, FTC, and TDF are confirmed by comparison of their retention times with those of the reference standards.
- the strength and degradation product content of EFV/FTC/TDF tablets is determined by the analysis of a composite solution prepared from ten tablets.
- the final concentration of each component in the sample solution is approximately 0.6 mg/m L of EFV, 0.2 mg/mL of FTC, and 0.3 mg/mL of TDF.
- An HPLC equipped with a UV detector and an electronic data acquisition system is used.
- Mobile phase buffer Prepare a 20 mM ammonium acetate buffer, pH 4.6; adjust pH with acetic acid as needed.
- the retention times of the FTC, TDF and EFV peaks are typically 11, 33, and 50 minutes, respectively
- N the number of theoretical plates
- T the tailing factors
- FTU Determined area percent of FTU determined for the sensitivity check standard or standard solution
- the sensitivity must be between 0.70-1.30.
- RRT retention ⁇ ⁇ time ⁇ ⁇ of ⁇ ⁇ the ⁇ ⁇ secondary ⁇ ⁇ peak retention ⁇ ⁇ time ⁇ ⁇ of ⁇ ⁇ the ⁇ ⁇ tenofovir ⁇ ⁇ disoproxil ⁇ ⁇ peak
- RRTs and the relative response factor (RRF) values of the potential impurities and degradation products for EFV are shown in Table 1, and the degradation products are shown in bold-face.
- the impurities and degradation products for FTC are shown in Table 2, and the degradation products are in bold-face.
- the impurities and degradation products for TDF are shown in Table 3, and the degradation products are in bold face.
- the identity of impurities and degradation products may be confirmed by comparison to authentic substances (or to impurity and degradation product peaks in the reference standard), if required.
- I Area of the degradation product peak or unassigned peak
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/452,472 US20070077295A1 (en) | 2005-06-13 | 2006-06-13 | Method and composition for pharmaceutical product |
US13/953,577 US8871271B2 (en) | 2005-06-13 | 2013-07-29 | Method and composition for pharmaceutical product |
US14/472,511 US20140370102A1 (en) | 2005-06-13 | 2014-08-29 | Method and composition for pharmaceutical product |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69001005P | 2005-06-13 | 2005-06-13 | |
US77135306P | 2006-02-07 | 2006-02-07 | |
US11/452,472 US20070077295A1 (en) | 2005-06-13 | 2006-06-13 | Method and composition for pharmaceutical product |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/953,577 Continuation US8871271B2 (en) | 2005-06-13 | 2013-07-29 | Method and composition for pharmaceutical product |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070077295A1 true US20070077295A1 (en) | 2007-04-05 |
Family
ID=37532912
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/452,472 Abandoned US20070077295A1 (en) | 2005-06-13 | 2006-06-13 | Method and composition for pharmaceutical product |
US13/953,577 Active US8871271B2 (en) | 2005-06-13 | 2013-07-29 | Method and composition for pharmaceutical product |
US14/472,511 Abandoned US20140370102A1 (en) | 2005-06-13 | 2014-08-29 | Method and composition for pharmaceutical product |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/953,577 Active US8871271B2 (en) | 2005-06-13 | 2013-07-29 | Method and composition for pharmaceutical product |
US14/472,511 Abandoned US20140370102A1 (en) | 2005-06-13 | 2014-08-29 | Method and composition for pharmaceutical product |
Country Status (22)
Country | Link |
---|---|
US (3) | US20070077295A1 (zh) |
EP (1) | EP1890681B1 (zh) |
JP (3) | JP5409001B2 (zh) |
CN (2) | CN104523713A (zh) |
AR (1) | AR054511A1 (zh) |
AT (1) | ATE419839T1 (zh) |
AU (1) | AU2006257794B2 (zh) |
CA (1) | CA2611520C (zh) |
CY (1) | CY1108973T1 (zh) |
DE (1) | DE602006004731D1 (zh) |
DK (1) | DK1890681T3 (zh) |
ES (1) | ES2320039T3 (zh) |
HK (1) | HK1109861A1 (zh) |
HR (1) | HRP20090194T1 (zh) |
MX (1) | MX2007015764A (zh) |
NZ (1) | NZ564045A (zh) |
PL (1) | PL1890681T3 (zh) |
PT (1) | PT1890681E (zh) |
RS (1) | RS50812B (zh) |
SI (1) | SI1890681T1 (zh) |
TW (1) | TWI375560B (zh) |
WO (1) | WO2006135932A2 (zh) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090036408A1 (en) * | 2003-01-14 | 2009-02-05 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
US20100081628A1 (en) * | 2008-06-11 | 2010-04-01 | Pharmasset, Inc. | Nucleoside cyclicphosphates |
WO2010075517A2 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Nucleoside analogs |
WO2010075549A2 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Nucleoside phosphoramidates |
WO2010075554A1 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Synthesis of purine nucleosides |
WO2010135569A1 (en) | 2009-05-20 | 2010-11-25 | Pharmasset, Inc. | N- [ (2 ' r) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-p-phenyl-5 ' -uridylyl] -l-alanine 1-methylethyl ester and process for its production |
WO2011123645A2 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Nucleoside phosphoramidates |
WO2011123672A1 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Purine nucleoside phosphoramidate |
WO2012075140A1 (en) | 2010-11-30 | 2012-06-07 | Pharmasset, Inc. | Compounds |
US8486942B2 (en) | 2007-02-23 | 2013-07-16 | Gilead Sciencs, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
US8598185B2 (en) | 2005-06-13 | 2013-12-03 | Bristol-Myers Squibb & Gilead Sciences, Inc. | Unitary pharmaceutical dosage form |
US20140277687A1 (en) * | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Process for drying a wet film with control of loss on drying |
US8871271B2 (en) | 2005-06-13 | 2014-10-28 | Gilead Sciences, Inc. | Method and composition for pharmaceutical product |
US20150141376A1 (en) * | 2013-11-18 | 2015-05-21 | Chandrashekhar Kandi | Pharmaceutical compositions of anti-viral compounds and process for preparation thereof |
US9139541B2 (en) | 2006-07-07 | 2015-09-22 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
EP3316868B1 (en) | 2015-06-30 | 2020-02-19 | Gilead Sciences, Inc. | Pharmaceutical formulations comprising tenofovir and emtricitabine |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010011963A (es) | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
AU2009318202A1 (en) * | 2008-11-21 | 2011-07-07 | Ultimorphix Technologies B.V. | Wet granulation of Tenofovir, Emtricitabine and Efavirenz |
AU2010210598B2 (en) | 2009-02-06 | 2015-03-05 | Gilead Sciences, Inc. | Tablets for combination therapy |
WO2011060256A2 (en) * | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Bilayer tablet formulations |
EP2377862A1 (en) * | 2010-03-29 | 2011-10-19 | Esteve Química, S.A. | Process for obtaining emtricitabine |
CN106511357A (zh) * | 2010-11-19 | 2017-03-22 | 吉利德科学公司 | 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物 |
MX2016002560A (es) | 2013-08-29 | 2016-10-26 | Teva Pharma | Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir. |
CA2942877A1 (en) | 2014-04-08 | 2015-10-15 | Nitzan SHAHAR | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir |
CN105125511A (zh) * | 2014-05-30 | 2015-12-09 | 北京星昊医药股份有限公司 | 一种富马酸替诺福韦酯片及其制备方法 |
CN106539807B (zh) * | 2015-09-21 | 2020-06-26 | 四川海思科制药有限公司 | 一种稳定的药物组合物及其制备方法 |
CN106749409A (zh) * | 2016-11-30 | 2017-05-31 | 宁波美诺华药业股份有限公司 | 一种替诺福韦酯富马酸盐二聚体杂质的合成方法 |
US10561614B2 (en) | 2017-01-27 | 2020-02-18 | Steerlife India Private Limited | Tenofovir granules |
RU2644156C1 (ru) | 2017-02-28 | 2018-02-08 | Александр Васильевич Иващенко | Пролекарство ингибитора NS5B HCV полимеразы, способ его получения и применения |
RU2662160C9 (ru) * | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
TR201713954A2 (tr) * | 2017-09-20 | 2019-04-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari |
WO2021091498A1 (en) * | 2019-11-06 | 2021-05-14 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Pharmaceutical compositions comprising tenofovir and emtricitabine |
CN111407736A (zh) * | 2020-03-30 | 2020-07-14 | 苏州弘森药业股份有限公司 | 一种富马酸替诺福韦二吡呋酯片的制备工艺 |
Citations (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3524846A (en) * | 1967-06-02 | 1970-08-18 | Syntex Corp | Process for the didealkylation of phosphonate esters |
US3622677A (en) * | 1969-07-07 | 1971-11-23 | Staley Mfg Co A E | Compressed tablets containing compacted starch as binder-disintegrant ingredient |
US3682930A (en) * | 1970-03-11 | 1972-08-08 | Jean Pierre Bourquin | 4(1-alkyl-4-piperidylidine)-4h-benzo {84,5{9 {0 cyclohepta {8 1,2{14 6{9 |
US3994974A (en) * | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
US4003878A (en) * | 1972-12-07 | 1977-01-18 | Avtex Fibers Inc. | Method of preparing an alkali-metal salt of an alkoxysulfonated benzoic acid glycol ester |
US4258062A (en) * | 1976-10-09 | 1981-03-24 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Phenoxy-amino-propanols |
US4355032A (en) * | 1981-05-21 | 1982-10-19 | Syntex (U.S.A.) Inc. | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent |
US4384005A (en) * | 1980-09-26 | 1983-05-17 | General Foods Corporation | Non-friable, readily-soluble, compressed tablets and process for preparing same |
US4430343A (en) * | 1981-11-06 | 1984-02-07 | Kanebo, Ltd. | Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same |
US4476248A (en) * | 1983-02-28 | 1984-10-09 | The Upjohn Company | Crystallization of ibuprofen |
US4808716A (en) * | 1985-04-25 | 1989-02-28 | Ceskoslovenska Akademic Ved | 9-(phosponylmethoxyalkyl) adenines, the method of preparation and utilization thereof |
US4879288A (en) * | 1986-03-27 | 1989-11-07 | Ici Americas Inc. | Novel dibenzothiazepine antipsychotic |
US4957924A (en) * | 1987-08-15 | 1990-09-18 | Burroughs Wellcome Co. | Therapeutic valine esters of acyclovir and pharmaceutically acceptable salts thereof |
US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5075445A (en) * | 1983-08-18 | 1991-12-24 | Beecham Group P.L.C. | Guanine derivatives |
US5142051A (en) * | 1986-07-18 | 1992-08-25 | Ceskoslovenska Akademie Ved | N-phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases and a therapeutical composition therefrom with antiviral activity |
US5155268A (en) * | 1984-05-04 | 1992-10-13 | The Upjohn Company | Antiarrhythmic N-aminoalkylene alkyl and aryl sulfonamides |
US5177064A (en) * | 1990-07-13 | 1993-01-05 | University Of Florida | Targeted drug delivery via phosphonate derivatives |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5208221A (en) * | 1990-11-29 | 1993-05-04 | Bristol-Myers Squibb Company | Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives |
US5476938A (en) * | 1990-08-10 | 1995-12-19 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Process for the preparation of nucleotides |
US5506347A (en) * | 1993-02-03 | 1996-04-09 | Gensia, Inc. | Lyxofuranosyl analogues of adenosine |
US5512596A (en) * | 1994-09-02 | 1996-04-30 | Gilead Sciences, Inc. | Aromatic compounds |
US5514798A (en) * | 1993-06-02 | 1996-05-07 | Gilead Sciences, Inc. | Method and cyclic carbonates for nucleotide analogues |
US5618964A (en) * | 1995-06-07 | 1997-04-08 | Bristol-Myers Squibb Company | Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method |
US5798340A (en) * | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US6121315A (en) * | 1996-09-20 | 2000-09-19 | Warner-Lambert Company | Oral compositions containing a zinc compound |
US6194391B1 (en) * | 1998-06-24 | 2001-02-27 | Emory University | 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol |
US20010012518A1 (en) * | 1998-04-07 | 2001-08-09 | Makooi-Morehead William T. | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
US20010014352A1 (en) * | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
US20030203969A1 (en) * | 2000-02-02 | 2003-10-30 | Dorian Bevec | Pharmaceutically active aromatic guanylhydrazones |
US20040180089A1 (en) * | 2002-12-26 | 2004-09-16 | Pozen Inc. | Multilayer dosage forms containing NSAIDs and triptans |
US20040224917A1 (en) * | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
US20040253218A1 (en) * | 1998-05-19 | 2004-12-16 | Yeda Research And Development Co., Ltd. | Method for reducing neuronal degeneration so as to ameliorate the effects of injury or disease |
US20060128692A1 (en) * | 2002-04-26 | 2006-06-15 | Gilead Sciences, Inc | Non nucleoside reverse transcriptase inhibitors |
US7094413B2 (en) * | 2002-01-24 | 2006-08-22 | Sangstat Medical Corporation | Combined therapy for treatment of HIV infection |
US20070036861A1 (en) * | 2003-06-06 | 2007-02-15 | Ethypharm | Orally-dispersible multilayer tablet |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH389608A (de) | 1960-01-19 | 1965-03-31 | Sandoz Ag | Verfahren zur Herstellung von neuen Äthern |
GB1523865A (en) | 1974-09-02 | 1978-09-06 | Wellcome Found | Purine compunds and salts thereof |
GB2111043B (en) | 1980-12-12 | 1985-02-06 | Ciba Geigy Ag | Novel cephalosporin esters |
US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
EP0182024B1 (en) | 1984-09-20 | 1991-04-03 | Beecham Group Plc | Purine derivatives and their pharmaceutical use |
CS263952B1 (en) | 1985-04-25 | 1989-05-12 | Holy Antonin | Remedy with antiviral effect |
US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
NZ222553A (en) | 1986-11-18 | 1991-07-26 | Bristol Myers Co | Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions |
DE3790883T1 (zh) | 1987-01-20 | 1988-12-08 | ||
ZA885709B (en) | 1987-08-19 | 1989-04-26 | Fujisawa Pharmaceutical Co | Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid(syn isomer) |
US5466806A (en) | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
CA2001715C (en) | 1988-11-14 | 1999-12-28 | Muzammil M. Mansuri | Carbocyclic nucleosides and nucleotides |
UA45942A (uk) | 1989-02-08 | 2002-05-15 | Біокем Фарма, Інк. | 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція |
US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US5728575A (en) | 1990-02-01 | 1998-03-17 | Emory University | Method of resolution of 1,3-oxathiolane nucleoside enantiomers |
GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
WO1991019721A1 (en) | 1990-06-13 | 1991-12-26 | Arnold Glazier | Phosphorous produgs |
HU9300132D0 (en) | 1990-07-19 | 1993-04-28 | Beecham Group Plc | Method for producing phosphono-alkene-purine derivatives and medical preparatives of anti-viral effect containing them |
EP0481214B1 (en) | 1990-09-14 | 1998-06-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Prodrugs of phosphonates |
CA2054126A1 (en) | 1990-10-26 | 1992-04-27 | Michiyuki Sendai | Cephem compounds, their production and use |
US5587480A (en) | 1990-11-13 | 1996-12-24 | Biochem Pharma, Inc. | Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties |
GB9026164D0 (en) | 1990-12-01 | 1991-01-16 | Beecham Group Plc | Pharmaceuticals |
US5179104A (en) | 1990-12-05 | 1993-01-12 | University Of Georgia Research Foundation, Inc. | Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides |
US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
NZ250842A (en) | 1991-02-22 | 1996-03-26 | Univ Emory | Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc) |
US6812233B1 (en) | 1991-03-06 | 2004-11-02 | Emory University | Therapeutic nucleosides |
CZ285232B6 (cs) | 1991-05-16 | 1999-06-16 | Glaxo Group Limited | Protivirové směsi |
GB9110874D0 (en) | 1991-05-20 | 1991-07-10 | Iaf Biochem Int | Medicaments |
ZA923641B (en) | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
GB9111902D0 (en) | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
GB9116601D0 (en) | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
ATE173267T1 (de) | 1992-06-23 | 1998-11-15 | Yamanouchi Pharma Co Ltd | Neues kristall von heterozyclischen bis(phosphonsäure) monohydrat-derivat |
US5532225A (en) | 1992-07-31 | 1996-07-02 | Sri International | Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods |
US5432172A (en) | 1992-08-03 | 1995-07-11 | The Research Foundation Of State University Of New York | Biological applications of alkaloids derived from the tunicate Eudistoma sp. |
US6057305A (en) | 1992-08-05 | 2000-05-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Antiretroviral enantiomeric nucleotide analogs |
US5665720A (en) | 1992-08-07 | 1997-09-09 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
GB9311709D0 (en) | 1993-06-07 | 1993-07-21 | Iaf Biochem Int | Stereoselective synthesis of nucleoside analogues using bicycle intermediate |
CA2126601A1 (en) | 1993-06-29 | 1994-12-30 | Mitsubishi Chemical Corporation | Phosphonate-nucleotide ester derivatives |
WO1995007920A1 (en) | 1993-09-17 | 1995-03-23 | Gilead Sciences, Inc. | Nucleotide analogs |
KR100386685B1 (ko) | 1993-09-17 | 2003-12-31 | 길리애드 사이언시즈, 인코포레이티드 | 뉴클레오타이드동족체류 |
WO1995032957A1 (en) | 1994-05-27 | 1995-12-07 | Astra Aktiebolag | Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles |
US5514557A (en) | 1994-06-06 | 1996-05-07 | Genetic Testing Institute Inc. | Method and kit for detecting antibodies specific for HLA and/or platelet glycoproteins |
PE32296A1 (es) | 1994-07-28 | 1996-08-07 | Hoffmann La Roche | Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables |
US5684018A (en) | 1994-12-13 | 1997-11-04 | Merck & Co., Inc. | Acyloxyisopropyl carbamates as prodrugs for amine drugs |
US5733788A (en) | 1996-07-26 | 1998-03-31 | Gilead Sciences, Inc. | PMPA preparation |
CA2261619C (en) | 1996-07-26 | 2006-05-23 | Gilead Sciences, Inc. | Nucleotide analogs |
US6113920A (en) | 1996-10-31 | 2000-09-05 | Glaxo Wellcome Inc. | Pharmaceutical compositions |
US5965729A (en) | 1997-02-05 | 1999-10-12 | Merck & Co., Inc. | Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent |
DK1256584T3 (da) | 1997-07-25 | 2004-12-06 | Gilead Sciences Inc | Fremgangsmåde til fremstilling af adefovir-dipivoxil |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
CO4970782A1 (es) | 1997-11-13 | 2000-11-07 | Merck & Co Inc | Terapia combinada para el tratamiento del sida |
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
EP1332757B1 (en) * | 1998-05-27 | 2012-06-13 | Merck Sharp & Dohme Corp. | Efavirenz compressed tablet formulation |
CO5070643A1 (es) | 1998-05-27 | 2001-08-28 | Merck & Co Inc | Formulacion en tabletas comprimidas |
DK1380303T3 (da) | 1998-11-02 | 2008-12-01 | Gilead Sciences Inc | Kombinationsterapi til behandling af hepatitis B-virus |
RS51561B (sr) | 2000-02-29 | 2011-08-31 | Bristol-Myers Squibb Co. | Formulacija male doze entekavira i upotreba |
CN1291994C (zh) | 2000-07-21 | 2006-12-27 | 吉里德科学公司 | 核苷酸膦酸酯类似物前药及其筛选和制备方法 |
JP2005500252A (ja) | 2000-12-15 | 2005-01-06 | トライアングル・フアーマシユーテイカルズ・インコーポレイテツド | リバビリン又はマイコフェノール酸などのimdph阻害剤とdapdの併用療法 |
US6900315B2 (en) | 2001-02-06 | 2005-05-31 | Yale University | 2-amino-9H-purin-9-yl compounds and methods for inhibiting/treating HIV infections and AIDS related symptoms |
DK1389207T3 (da) | 2001-03-01 | 2006-04-18 | Gilead Sciences Inc | Polymorfe og andre krystallinske former af cis-FTC |
US20020187957A1 (en) * | 2001-05-30 | 2002-12-12 | Bruce Halstead | Time release reverse transcriptase inhibitors |
MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
US20030124186A1 (en) * | 2001-11-27 | 2003-07-03 | Hussain Munir A. | Efavirenz tablet formulation having unique biopharmaceutical characteristics |
PT2260833E (pt) | 2002-01-16 | 2012-12-26 | Boehringer Ingelheim Pharma | Comprimido farmacêutico de duas camadas compreendendo telmisartan e um diurético |
CA2502625A1 (en) | 2002-12-09 | 2004-06-24 | The University Of Georgia Research Foundation, Inc. | Dioxolane thymine and combinations for use against resistant strains of hiv |
US6930093B2 (en) * | 2003-07-10 | 2005-08-16 | Valeant Research & Development | Use of ribofuranose derivatives against inflammatory bowel diseases |
CA2598607A1 (en) | 2005-01-18 | 2006-07-27 | Adra N. Chaker | Methods and compositions for cell-cycle regulation |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
CA2612788A1 (en) | 2005-06-24 | 2006-12-28 | Steven Cesar Alfons De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c |
AP2008004533A0 (en) | 2005-12-14 | 2008-08-31 | Cipla Ltd | Pharmaceutical combination |
GB0525898D0 (en) | 2005-12-20 | 2006-02-01 | Pharmo Bioscience As | Screening compounds for activity in modulating chloride ion transport |
AU2008206695A1 (en) | 2007-01-16 | 2008-07-24 | Proteologics Ltd | Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors |
-
2006
- 2006-06-08 TW TW095120445A patent/TWI375560B/zh active
- 2006-06-12 AR ARP060102467A patent/AR054511A1/es unknown
- 2006-06-13 CN CN201410690960.5A patent/CN104523713A/zh active Pending
- 2006-06-13 US US11/452,472 patent/US20070077295A1/en not_active Abandoned
- 2006-06-13 DK DK06773194T patent/DK1890681T3/da active
- 2006-06-13 PT PT06773194T patent/PT1890681E/pt unknown
- 2006-06-13 CA CA2611520A patent/CA2611520C/en active Active
- 2006-06-13 WO PCT/US2006/023222 patent/WO2006135932A2/en active Application Filing
- 2006-06-13 AU AU2006257794A patent/AU2006257794B2/en active Active
- 2006-06-13 DE DE602006004731T patent/DE602006004731D1/de active Active
- 2006-06-13 ES ES06773194T patent/ES2320039T3/es active Active
- 2006-06-13 RS RSP-2009/0121A patent/RS50812B/sr unknown
- 2006-06-13 MX MX2007015764A patent/MX2007015764A/es active IP Right Grant
- 2006-06-13 CN CN200680026180.4A patent/CN101222914B/zh active Active
- 2006-06-13 PL PL06773194T patent/PL1890681T3/pl unknown
- 2006-06-13 NZ NZ564045A patent/NZ564045A/en unknown
- 2006-06-13 AT AT06773194T patent/ATE419839T1/de active
- 2006-06-13 SI SI200630247T patent/SI1890681T1/sl unknown
- 2006-06-13 JP JP2008517083A patent/JP5409001B2/ja active Active
- 2006-06-13 EP EP06773194A patent/EP1890681B1/en not_active Revoked
-
2008
- 2008-04-10 HK HK08104026.2A patent/HK1109861A1/xx not_active IP Right Cessation
-
2009
- 2009-04-03 HR HR20090194T patent/HRP20090194T1/xx unknown
- 2009-04-03 CY CY20091100392T patent/CY1108973T1/el unknown
-
2011
- 2011-12-27 JP JP2011286646A patent/JP2012062332A/ja not_active Withdrawn
-
2013
- 2013-07-29 US US13/953,577 patent/US8871271B2/en active Active
-
2014
- 2014-08-29 US US14/472,511 patent/US20140370102A1/en not_active Abandoned
- 2014-10-14 JP JP2014209684A patent/JP2015007137A/ja active Pending
Patent Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3524846A (en) * | 1967-06-02 | 1970-08-18 | Syntex Corp | Process for the didealkylation of phosphonate esters |
US3622677A (en) * | 1969-07-07 | 1971-11-23 | Staley Mfg Co A E | Compressed tablets containing compacted starch as binder-disintegrant ingredient |
US3682930A (en) * | 1970-03-11 | 1972-08-08 | Jean Pierre Bourquin | 4(1-alkyl-4-piperidylidine)-4h-benzo {84,5{9 {0 cyclohepta {8 1,2{14 6{9 |
US3994974A (en) * | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
US4003878A (en) * | 1972-12-07 | 1977-01-18 | Avtex Fibers Inc. | Method of preparing an alkali-metal salt of an alkoxysulfonated benzoic acid glycol ester |
US4258062A (en) * | 1976-10-09 | 1981-03-24 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Phenoxy-amino-propanols |
US4384005A (en) * | 1980-09-26 | 1983-05-17 | General Foods Corporation | Non-friable, readily-soluble, compressed tablets and process for preparing same |
US4355032B1 (zh) * | 1981-05-21 | 1983-06-14 | ||
US4355032A (en) * | 1981-05-21 | 1982-10-19 | Syntex (U.S.A.) Inc. | 9-(1,3-Dihydroxy-2-propoxymethyl)guanine as antiviral agent |
US4355032B2 (en) * | 1981-05-21 | 1990-10-30 | 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent | |
US4430343A (en) * | 1981-11-06 | 1984-02-07 | Kanebo, Ltd. | Benzimidazole derivatives, process for the preparation thereof and pharmaceutical composition containing the same |
US4476248A (en) * | 1983-02-28 | 1984-10-09 | The Upjohn Company | Crystallization of ibuprofen |
US5075445A (en) * | 1983-08-18 | 1991-12-24 | Beecham Group P.L.C. | Guanine derivatives |
US5155268A (en) * | 1984-05-04 | 1992-10-13 | The Upjohn Company | Antiarrhythmic N-aminoalkylene alkyl and aryl sulfonamides |
US4808716A (en) * | 1985-04-25 | 1989-02-28 | Ceskoslovenska Akademic Ved | 9-(phosponylmethoxyalkyl) adenines, the method of preparation and utilization thereof |
US4879288A (en) * | 1986-03-27 | 1989-11-07 | Ici Americas Inc. | Novel dibenzothiazepine antipsychotic |
US5142051A (en) * | 1986-07-18 | 1992-08-25 | Ceskoslovenska Akademie Ved | N-phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases and a therapeutical composition therefrom with antiviral activity |
US4957924A (en) * | 1987-08-15 | 1990-09-18 | Burroughs Wellcome Co. | Therapeutic valine esters of acyclovir and pharmaceutically acceptable salts thereof |
US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5210085A (en) * | 1990-02-01 | 1993-05-11 | Emory University | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
US5177064A (en) * | 1990-07-13 | 1993-01-05 | University Of Florida | Targeted drug delivery via phosphonate derivatives |
US5476938A (en) * | 1990-08-10 | 1995-12-19 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Process for the preparation of nucleotides |
US5208221A (en) * | 1990-11-29 | 1993-05-04 | Bristol-Myers Squibb Company | Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives |
US5386030A (en) * | 1990-11-29 | 1995-01-31 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Science Of The Czech Republic | Antiviral (phosphonomethoxy)methoxy purine/pyrimidine derivatives |
US5506347A (en) * | 1993-02-03 | 1996-04-09 | Gensia, Inc. | Lyxofuranosyl analogues of adenosine |
US5514798A (en) * | 1993-06-02 | 1996-05-07 | Gilead Sciences, Inc. | Method and cyclic carbonates for nucleotide analogues |
US5798340A (en) * | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
US5512596A (en) * | 1994-09-02 | 1996-04-30 | Gilead Sciences, Inc. | Aromatic compounds |
US5618964A (en) * | 1995-06-07 | 1997-04-08 | Bristol-Myers Squibb Company | Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method |
US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US6121315A (en) * | 1996-09-20 | 2000-09-19 | Warner-Lambert Company | Oral compositions containing a zinc compound |
US20010012518A1 (en) * | 1998-04-07 | 2001-08-09 | Makooi-Morehead William T. | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants |
US20040253218A1 (en) * | 1998-05-19 | 2004-12-16 | Yeda Research And Development Co., Ltd. | Method for reducing neuronal degeneration so as to ameliorate the effects of injury or disease |
US20010014352A1 (en) * | 1998-05-27 | 2001-08-16 | Udit Batra | Compressed tablet formulation |
US6194391B1 (en) * | 1998-06-24 | 2001-02-27 | Emory University | 3′-azido-2′,3′-dideoxyuridine administration to treat HIV and related test protocol |
US20030203969A1 (en) * | 2000-02-02 | 2003-10-30 | Dorian Bevec | Pharmaceutically active aromatic guanylhydrazones |
US7094413B2 (en) * | 2002-01-24 | 2006-08-22 | Sangstat Medical Corporation | Combined therapy for treatment of HIV infection |
US20060128692A1 (en) * | 2002-04-26 | 2006-06-15 | Gilead Sciences, Inc | Non nucleoside reverse transcriptase inhibitors |
US20040180089A1 (en) * | 2002-12-26 | 2004-09-16 | Pozen Inc. | Multilayer dosage forms containing NSAIDs and triptans |
US20040224917A1 (en) * | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
US20070036861A1 (en) * | 2003-06-06 | 2007-02-15 | Ethypharm | Orally-dispersible multilayer tablet |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8592397B2 (en) | 2003-01-14 | 2013-11-26 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
US20090036408A1 (en) * | 2003-01-14 | 2009-02-05 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
US8716264B2 (en) | 2003-01-14 | 2014-05-06 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
US9744181B2 (en) | 2003-01-14 | 2017-08-29 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
US9457036B2 (en) | 2003-01-14 | 2016-10-04 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
US8871271B2 (en) | 2005-06-13 | 2014-10-28 | Gilead Sciences, Inc. | Method and composition for pharmaceutical product |
US9018192B2 (en) | 2005-06-13 | 2015-04-28 | Bristol-Myers Squibb & Gilead Sciences, Inc. | Unitary pharmaceutical dosage form |
US9545414B2 (en) | 2005-06-13 | 2017-01-17 | Bristol-Myers Squibb & Gilead Sciences, Llc | Unitary pharmaceutical dosage form |
US8598185B2 (en) | 2005-06-13 | 2013-12-03 | Bristol-Myers Squibb & Gilead Sciences, Inc. | Unitary pharmaceutical dosage form |
US9139541B2 (en) | 2006-07-07 | 2015-09-22 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US9891239B2 (en) | 2007-02-23 | 2018-02-13 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US8486942B2 (en) | 2007-02-23 | 2013-07-16 | Gilead Sciencs, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US8759510B2 (en) | 2008-06-11 | 2014-06-24 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
US20100081628A1 (en) * | 2008-06-11 | 2010-04-01 | Pharmasset, Inc. | Nucleoside cyclicphosphates |
EP3222628A1 (en) | 2008-12-23 | 2017-09-27 | Gilead Pharmasset LLC | Nucleoside phosphoramidates |
US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
US9045520B2 (en) | 2008-12-23 | 2015-06-02 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
EP2671888A1 (en) | 2008-12-23 | 2013-12-11 | Gilead Pharmasset LLC | 3',5'-cyclic nucleoside phosphate analogues |
WO2010075554A1 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Synthesis of purine nucleosides |
US8716262B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8716263B2 (en) | 2008-12-23 | 2014-05-06 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
WO2010075549A2 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Nucleoside phosphoramidates |
US8957045B2 (en) | 2008-12-23 | 2015-02-17 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
WO2010075517A2 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Nucleoside analogs |
EP3321275A1 (en) | 2009-05-20 | 2018-05-16 | Gilead Pharmasset LLC | Crystalline form of sofosbuvir |
WO2010135569A1 (en) | 2009-05-20 | 2010-11-25 | Pharmasset, Inc. | N- [ (2 ' r) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-p-phenyl-5 ' -uridylyl] -l-alanine 1-methylethyl ester and process for its production |
EP2610264A2 (en) | 2009-05-20 | 2013-07-03 | Gilead Pharmasset LLC | N-[(2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl]-l-alanine 1-methylethyl ester and process for its production |
EP2910562A1 (en) | 2009-05-20 | 2015-08-26 | Gilead Pharmasset LLC | N-[(2'r)-2'-deoxy-2 '-fluoro-2'-methyl-p-phenyl-5 '-uridylyl]-l-alanine 1-methylethyl ester in crystalline form |
EP2913337A1 (en) | 2009-05-20 | 2015-09-02 | Gilead Pharmasset LLC | N-[(2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl]-l-alanine 1-methylethyl ester and process for its production |
WO2011123672A1 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Purine nucleoside phosphoramidate |
EP2752422A1 (en) | 2010-03-31 | 2014-07-09 | Gilead Pharmasset LLC | Stereoselective synthesis of phosphorus containing actives |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
EP2609923A2 (en) | 2010-03-31 | 2013-07-03 | Gilead Pharmasset LLC | Nucleoside Phosphoramidates |
US8859756B2 (en) | 2010-03-31 | 2014-10-14 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorus containing actives |
EP3290428A1 (en) | 2010-03-31 | 2018-03-07 | Gilead Pharmasset LLC | Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
WO2011123668A2 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Stereoselective synthesis of phosphorus containing actives |
WO2011123645A2 (en) | 2010-03-31 | 2011-10-06 | Pharmasset, Inc. | Nucleoside phosphoramidates |
WO2012075140A1 (en) | 2010-11-30 | 2012-06-07 | Pharmasset, Inc. | Compounds |
US9394331B2 (en) | 2010-11-30 | 2016-07-19 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
EP3042910A2 (en) | 2010-11-30 | 2016-07-13 | Gilead Pharmasset LLC | 2'-spiro-nucleosides for use in the therapy of hepatitis c |
US8841275B2 (en) | 2010-11-30 | 2014-09-23 | Gilead Pharmasset Llc | 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections |
US20140277687A1 (en) * | 2013-03-15 | 2014-09-18 | Monosol Rx, Llc | Process for drying a wet film with control of loss on drying |
US9303918B2 (en) * | 2013-03-15 | 2016-04-05 | Monosol Rx, Llc | Process for drying a wet film with control of loss on drying |
CN105229401A (zh) * | 2013-03-15 | 2016-01-06 | 莫诺索尔克斯有限公司 | 通过控制干燥失重使湿薄膜干燥的方法 |
US20150141376A1 (en) * | 2013-11-18 | 2015-05-21 | Chandrashekhar Kandi | Pharmaceutical compositions of anti-viral compounds and process for preparation thereof |
EP3316868B1 (en) | 2015-06-30 | 2020-02-19 | Gilead Sciences, Inc. | Pharmaceutical formulations comprising tenofovir and emtricitabine |
EP4070787B1 (en) | 2015-06-30 | 2023-03-01 | Gilead Sciences, Inc. | Pharmaceutical formulations |
EP4070788B1 (en) | 2015-06-30 | 2023-03-22 | Gilead Sciences, Inc. | Pharmaceutical formulations |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8871271B2 (en) | Method and composition for pharmaceutical product | |
US9018192B2 (en) | Unitary pharmaceutical dosage form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GILEAD SCIENCES, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DAHL, TERRENCE C.;MENNING, MARK M.;OLIYAI, REZA;AND OTHERS;REEL/FRAME:018726/0391 Effective date: 20061206 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |